Selexis SA, a JSR Life Sciences Company, is a global leader in cell line development, specializing in modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. The company serves pharmaceutical and biotechnology firms, focusing on the development of high-tech medicines for the treatment of rare diseases such as PNH and aHUS. Selexis operates in the biopharmaceutical market, leveraging its proprietary gene technologies to advance over 130 drug products in clinical development and the manufacture of seven commercial products. The business model revolves around providing cell line development technologies that shorten development timelines and reduce manufacturing risks, thereby accelerating the drug development process. Selexis generates revenue through partnerships and collaborations with global pharmaceutical companies, offering its cutting-edge cell line generation and protein expression technologies. The company’s expertise in mammalian suspension adapted CHO K1 cell line generation has set new benchmarks in bioproduction for over a decade.

Keywords: cell line development, biopharmaceuticals, gene technologies, protein expression, CHO K1, drug development, rare diseases, modular technology, bioproduction, life sciences.